Genetic stability of Brucella abortus S19 and RB51 vaccine strains by multiple locus variable number tandem repeat analysis (MLVA16)

Highlights • The tested S19 and RB51 commercial vaccines proved to be genetically homogeneous among themselves. • All batches showed genotypes identical to S19 and RB51 reference strains, except batches from one S19 and one RB51 producers. • MLVA16 genotypes of S19 and RB51 strains were stable throu...

Full description

Saved in:
Bibliographic Details
Published in:Vaccine 2013-10, Vol.31 (42), p.4856-4859
Main Authors: Dorneles, Elaine Maria Seles, de Faria, Ana Paula Paiva, Pauletti, Rebeca Barbosa, Santana, Jordana Almeida, Caldeira, George Afonso Vítor, Heinemann, Marcos Bryan, Titze-de-Almeida, Ricardo, Lage, Andrey Pereira
Format: Article
Language:English
Subjects:
Allergy and Immunology
Applied microbiology
Bacterial diseases
Bacteriology
Biological and medical sciences
Brucella abortus
Brucella abortus - genetics
Brucella melitensis biovar Abortus
Brucella Vaccine - genetics
Brucellosis
DNA Fingerprinting
DNA, Bacterial - genetics
Drug Stability
Fundamental and applied biological sciences. Psychology
genetic stability
Genomic Instability
Genotype
Genotyping
Human bacterial diseases
Infectious diseases
live vaccines
loci
Medical sciences
Microbiology
Minisatellite Repeats
Miscellaneous
MLVA16
quality control
Vaccines
Vaccines, antisera, therapeutical immunoglobulins and monoclonal antibodies (general aspects)
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Highlights • The tested S19 and RB51 commercial vaccines proved to be genetically homogeneous among themselves. • All batches showed genotypes identical to S19 and RB51 reference strains, except batches from one S19 and one RB51 producers. • MLVA16 genotypes of S19 and RB51 strains were stable through 10 in vitro serial passages. • MLVA16 should be included among official tests required for approval of vaccines against brucellosis.
ISSN:0264-410X
1873-2518
DOI:10.1016/j.vaccine.2013.07.063